Literature DB >> 11669218

Effects of extending the duration of postgrafting immunosuppression and substituting granulocyte-colony-stimulating factor-mobilized peripheral blood mononuclear cells for marrow in allogeneic engraftment in a nonmyeloablative canine transplantation model.

J M Zaucha1, C Yu, E Zellmer, A Takatu, C Junghanss, M T Little, R Storb.   

Abstract

Stable mixed donor/host hematopoietic chimerism was uniformly achieved in dogs given 200 cGy total body irradiation (TBI) before and immunosuppression with mycophenolate mofetil (MMF) for 28 days and cyclosporine (CSP) for 35 days after transplantation of marrow from dog leukocyte antigen-identical littermates. When the TBI dose was lowered to 100 cGy, donor marrow engraftment in 6 dogs was only transient, lasting 3 to 12 weeks. In this study, we asked whether stable engraftment in this model could be achieved: (1) by substituting recombinant canine granulocyte-colony-stimulating factor-mobilized peripheral blood mononuclear cells (G-PBMCs) for marrow and (2) by extending CSP administration from 35 to 100 days. Eighteen dogs were given G-PBMC grafts and MMF for 28 days. Eight of the 18 dogs received CSP for 35 days and 10 for 100 days. We found that substituting G-PBMCs for marrow did not increase the incidence of stable allogeneic engraftment (P = .11). However, increasing the duration of posttransplantation immunosuppression with CSP from 35 to 100 days favorably influenced stable donor engraftment (P = .06).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11669218     DOI: 10.1053/bbmt.2001.v7.pm11669218

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  7 in total

Review 1.  Allogeneic hematopoietic cell transplantation: from experimental biology to clinical care.

Authors:  Razvan Diaconescu; Rainer Storb
Journal:  J Cancer Res Clin Oncol       Date:  2004-09-28       Impact factor: 4.553

2.  A preclinical model of double- versus single-unit unrelated cord blood transplantation.

Authors:  George E Georges; Vladimir Lesnikov; Szczepan W Baran; Anna Aragon; Marina Lesnikova; Robert Jordan; Ya-Ju Laura Yang; Murad Y Yunusov; Eustacia Zellmer; Shelly Heimfeld; Gopalakrishnan M Venkataraman; Michael A Harkey; Scott S Graves; Rainer Storb; Barry E Storer; Richard A Nash
Journal:  Biol Blood Marrow Transplant       Date:  2010-03-18       Impact factor: 5.742

3.  Investigation of immunological approaches to enhance engraftment in a 1 Gy TBI canine hematopoietic stem cell transplantation model.

Authors:  Sandra Lange; Simone Altmann; Bettina Brandt; Carsten Adam; Franziska Riebau; Heike Vogel; Volker Weirich; Inken Hilgendorf; Rainer Storb; Mathias Freund; Christian Junghanss
Journal:  Exp Hematol       Date:  2009-01       Impact factor: 3.084

4.  Canine DLA-79 gene: an improved typing method, identification of new alleles and its role in graft rejection and graft-versus-host disease.

Authors:  G M Venkataraman; D Geraghty; J Fox; S S Graves; E Zellmer; B E Storer; B J Torok-Storb; R Storb
Journal:  Tissue Antigens       Date:  2013-04

Review 5.  Developments and translational relevance for the canine haematopoietic cell transplantation preclinical model.

Authors:  Scott S Graves; Rainer Storb
Journal:  Vet Comp Oncol       Date:  2020-05-26       Impact factor: 2.385

Review 6.  Evolution of haematopoietic cell transplantation for canine blood disorders and a platform for solid organ transplantation.

Authors:  Scott S Graves; Rainer Storb
Journal:  Vet Med Sci       Date:  2021-08-14

7.  Myeloid Leukemias and Virally Induced Lymphomas in Miniature Inbred Swine: Development of a Large Animal Tumor Model.

Authors:  Raimon Duran-Struuck; Abraham J Matar; Christene A Huang
Journal:  Front Genet       Date:  2015-11-20       Impact factor: 4.599

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.